The short answer
HIV is not a contraindication to menopausal hormone therapy. The usual safety considerations still apply, and a clinician checks your antiretroviral regimen for interactions. Transdermal estradiol is often preferred because it avoids first-pass liver metabolism and carries a lower clot risk than oral estrogen. Most modern unboosted regimens have no clinically significant interaction; boosted protease inhibitors, cobicistat and some NNRTIs can change hormone levels, which is usually managed by adjusting the hormone dose.
This guide runs no advertising or analytics trackers. Reading it is never linked to your identity. Our privacy pledge
Is HRT safe with HIV?
Major HIV and menopause guidance treats women living with HIV the same as other women when deciding about hormone therapy: the benefits and risks are weighed for the individual. HIV itself is not a reason to withhold treatment.
The general contraindications still apply, including current or past breast cancer, unexplained vaginal bleeding, active liver disease, a history of blood clots or stroke in some situations, and uncontrolled high blood pressure. Your clinician reviews these the same way for everyone.
For most healthy women under 60 or within 10 years of menopause, The Menopause Society concludes the benefits of hormone therapy for bothersome symptoms and bone protection generally outweigh the risks.
Why transdermal estradiol is often preferred
Estradiol can be taken as a patch, gel or spray (transdermal) or as a tablet. Transdermal estradiol enters the bloodstream directly through the skin, so it avoids the first pass through the liver.
- Lower risk of blood clots than oral estrogen in observational studies, which matters because HIV is associated with a higher clot and cardiovascular risk.
- Less effect on liver proteins and triglycerides.
- Steadier hormone levels, and doses that are easy to adjust if an interaction lowers or raises levels.
- A good option for women with hepatitis B or C coinfection or raised liver enzymes, once a clinician has reviewed liver health.
Protecting the womb lining
If you have a uterus, estrogen is combined with a progestogen to prevent thickening of the lining (endometrial hyperplasia). Options include micronized progesterone, other progestins taken by mouth or as part of a combined patch, and the levonorgestrel intrauterine system (hormonal IUD).
The hormonal IUD releases its progestogen mainly inside the uterus. It is often a practical choice when ART interactions affect oral progestogens, and it also provides contraception during perimenopause.
ART and hormone therapy: what interacts
Interactions mostly affect hormone levels, not the effectiveness of your HIV medicines. Clinicians check each combination against current interaction resources, such as the University of Liverpool HIV Drug Interactions checker, because guidance is updated as new data emerge.
| ART class or booster | Examples | Possible effect on hormones | Usual approach |
|---|---|---|---|
| Unboosted integrase inhibitors | Dolutegravir, bictegravir, raltegravir, cabotegravir | No clinically significant interaction expected | Standard dosing |
| Newer NNRTIs | Rilpivirine, doravirine | No clinically significant interaction expected | Standard dosing |
| Ritonavir-boosted protease inhibitors | Darunavir/r, atazanavir/r, lopinavir/r | Estradiol levels may fall; some progestogen levels may rise | Titrate estradiol to symptoms; choose progestogen with interaction review |
| Cobicistat-boosted regimens | Elvitegravir/c, darunavir/c, atazanavir/c | Can alter estrogen and raise some progestogen levels | Interaction review; dose adjustment by symptoms |
| Enzyme-inducing NNRTIs | Efavirenz, nevirapine, etravirine | Estrogen and progestogen levels may fall | May need higher estradiol dose; consider hormonal IUD for endometrial protection |
| NRTI backbones | Tenofovir (TDF or TAF), emtricitabine, lamivudine, abacavir | No clinically significant hormone interaction expected | Standard dosing; TDF is relevant to bone health |
If an interaction matters, the usual step is to adjust the hormone treatment and follow your symptoms. Changing ART for menopause care is rarely necessary and is always a decision for your HIV clinician.
Benefits to expect
- Relief of hot flashes and night sweats, usually within weeks.
- Better sleep, and often improvements in mood, joint aches and quality of life.
- Prevention of bone loss and reduced fracture risk, which is important given higher bone risks with HIV.
- Relief of vaginal dryness and urinary symptoms; vaginal estrogen can be used alone or with systemic HRT.
- Possible cardiovascular signals: starting hormone therapy before 60 or within 10 years of menopause has not shown the harms seen in older starters, but HRT is not prescribed to prevent heart disease.
Monitoring on hormone therapy
- A review of symptoms and side effects about 3 months after starting or changing a dose, then at least yearly.
- Dose adjustments guided by symptoms; blood estradiol levels are occasionally checked when an interaction is suspected or symptoms do not respond.
- Blood pressure, weight, and routine HIV monitoring as usual.
- Breast screening and cervical screening on schedule; women with HIV generally need cervical screening more often.
- Prompt review of any unexpected bleeding, especially after 6 months on a stable regimen.
- Sharing any ART change with your menopause clinician, and any hormone change with your HIV team.
What about testosterone?
For low sexual desire that causes distress after menopause, some clinicians consider low-dose transdermal testosterone. It is not FDA-approved for women in the United States, and the same ART interaction checks apply. It is never a first-line treatment for hot flashes.
Specialized care pathway
Menopause care that works alongside your HIV care
A private, step-by-step preparation tool. It builds a summary of your ART, symptoms and preferences for a licensed clinician. Your answers stay in your browser and are not saved or sent.
Questions, answered
Common questions
Is HRT contraindicated in HIV?
+
No. HIV is not a contraindication to hormone therapy. The same individual safety assessment applies as for any woman.
Which HRT is best for women living with HIV?
+
There is no single best option, but transdermal estradiol is often preferred because of its lower clot risk and fewer liver effects. A progestogen, sometimes a hormonal IUD, is added if you have a uterus.
Does HRT interact with Biktarvy or dolutegravir?
+
Unboosted integrase inhibitor regimens such as bictegravir- or dolutegravir-based regimens are not expected to have clinically significant interactions with estradiol. Your clinician still confirms your exact combination.
Does HRT interact with ritonavir or cobicistat?
+
Boosted regimens can change hormone levels, often lowering estradiol and raising some progestogens. This is usually managed by adjusting the hormone dose based on symptoms and choosing the progestogen carefully.
Does efavirenz affect HRT?
+
Efavirenz and nevirapine can speed up hormone breakdown, lowering levels. A higher estradiol dose or a hormonal IUD for womb protection may be considered.
Will HRT make my viral load go up?
+
Estradiol is not expected to reduce the effectiveness of ART or raise viral load. Keep taking ART as prescribed and continue routine monitoring.
How long can I stay on HRT?
+
There is no fixed time limit. Duration is reviewed at least yearly with your clinician based on symptoms, benefits and your personal risks.
WRITTEN & MEDICALLY REVIEWED BY
Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team, led by Kevin Wolfe, CMO
Kindr’s clinical content is written and reviewed by board-certified clinicians who prescribe hormone therapy every day across all 50 states — menopause-focused physicians, nurse practitioners, and pharmacists working under Kindr Health, Inc.’s organizational clinical oversight. Every page is checked against current NAMS and ACOG guidance, FDA labeling, and the primary literature before publication, then re-reviewed on a rolling schedule when guidance changes.
Organizational NPI 1609792902 · Last reviewed October 4, 2026 · Editorial policy
Educational content only — not a substitute for individual medical advice, diagnosis, or treatment.
SOURCES & REFERENCES
Every clinical claim on this page is sourced.
- Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV: Women with HIV — U.S. Department of Health and Human Services (DHHS), Clinicalinfo.HIV.gov. clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/women-hiv
- HIV Drug Interactions Checker — University of Liverpool. www.hiv-druginteractions.org/checker
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society (2022) — The Menopause Society (formerly NAMS). www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf
- EACS Guidelines (drug-drug interactions, menopause, bone and cardiovascular sections) — European AIDS Clinical Society. www.eacsociety.org/guidelines/eacs-guidelines
- BHIVA guidelines, including monitoring and women’s health guidance — British HIV Association. www.bhiva.org/guidelines
- Guidelines for the Prevention and Treatment of Opportunistic Infections: Human Papillomavirus Disease — DHHS, Clinicalinfo.HIV.gov. clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/human-papillomavirus